Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
1CMFRA:IQ70 +40.00%50 Return-on-Tangible-Equity is 58.43% as of Feb. 2026. GuruFocus rates FRA:IQ70 with a GF Score™ of 50/100 and a GF Value™ of €0.13. The stock has 3 warning signs investors should review. Among 901 Drug Manufacturers companies, 1CM ranks better than 82.13% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. 1CM's annualized net income for the quarter that ended in Feb. 2026 was €9.72 Mil. 1CM's average shareholder tangible equity for the quarter that ended in Feb. 2026 was €16.63 Mil. Therefore, 1CM's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2026 was 58.43%.
The historical rank and industry rank for 1CM's Return-on-Tangible-Equity or its related term are showing as below:
FRA:IQ70'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1248.81 Med: -76.9 Max: 23.13
Current: 23.13
During the past 13 years, 1CM's highest Return-on-Tangible-Equity was 23.13%. The lowest was -1,248.81%. And the median was -76.90%.
FRA:IQ70's Return-on-Tangible-Equity is ranked better than 82.13% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs FRA:IQ70: 23.13
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
1CM Return-on-Tangible-Equity Related Terms
1CM Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for 1CM's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IQ70 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, 1CM's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
1CM Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, 1CM's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where 1CM's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Feb. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 58.43% mean?
1CM (FRA:IQ70) has a Return-on-Tangible-Equity of 58.43% as of Feb. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 1CM and its competitors. According to the industry distribution chart, 1CM ranks #161 out of 901 companies in the Drug Manufacturers industry, placing it in the top 17.9%.
Is 1CM's Return-on-Tangible-Equity too high?
1CM's current Return-on-Tangible-Equity is 58.43%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. 1CM's value of 58.43% is 639.6% above this industry median. Based on the distribution chart, 1CM ranks #161 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, 1CM has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does 1CM's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, 1CM ranks #161 out of 901 companies for Return-on-Tangible-Equity. This places 1CM in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. 1CM's value of 58.43% is 639.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 1CM's current Return-on-Tangible-Equity of 58.43% is 639.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 1CM and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 1CM's current Return-on-Tangible-Equity is 58.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 1CM stock overvalued right now?
1CM (FRA:IQ70) has a current Return-on-Tangible-Equity of 58.43%. The stock's GF Value™ is €0.13, compared to a current price of €0.04 — trading 73.1% below its estimated fair value. The current Return-on-Tangible-Equity is 58.43% and 639.6% above the Drug Manufacturers industry median of 7.90. 1CM's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For 1CM (FRA:IQ70), the current Return-on-Tangible-Equity is 58.43% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 1CM (FRA:IQ70) Overvalued in 2026?
Based on GuruFocus' analysis, 1CM stock appears to be undervalued.
The current stock price of €0.04 is trading 73.1% below its estimated GF Value™ of €0.13.
Key valuation signals for FRA:IQ70:
Return-on-Tangible-Equity: 58.43%
GF Value™: €0.13 vs. price of €0.04 (73.1% below fair value)
Industry Position: 639.6% above the Drug Manufacturers median (#161 of 901)
No single metric tells the full story. See the FRA:IQ70 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
1CM Inc is a multi-jurisdictional cannabis company focused on its retail customers and technology to democratize cannabis markets. The Company focuses on expanding its current operations through organic growth and by way of merger and acquisition transactions. It has a single operating segment, being Cannabis.
50GF Score
Get the complete analysis for FRA:IQ70
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IQ70 has been successfully added to your 
